Boehringer Ingelheim And Eli Lilly And Company Announces U.S. FDA Approves Jardiance For The Treatment Of Type 2 Diabetes In Children 10 Years And Older
Portfolio Pulse from Happy Mohamed
The U.S. FDA has approved Jardiance (empagliflozin) for the treatment of type 2 diabetes in children aged 10 and older. Jardiance, developed by Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY), is the first and only SGLT2 inhibitor approved for this patient population.
June 21, 2023 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly and Company's Jardiance has been approved by the FDA for treating type 2 diabetes in children aged 10 and older, expanding the drug's market.
The FDA approval of Jardiance for treating type 2 diabetes in children aged 10 and older is a significant milestone for Eli Lilly and Boehringer Ingelheim. This expands the drug's market and addresses a growing health concern among young people in the U.S. The approval is based on positive results from the DINAMO phase III trial, which demonstrated the drug's efficacy and safety. This is likely to have a positive short-term impact on Eli Lilly's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100